These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Effect of I,25-dihydroxycholecalciferol in renal osteodystrophy. Silverberg DS; Bettcher KB; Dossetor JB; Overton TR; Holick MF; DeLuca HF Can Med Assoc J; 1975 Jan; 112(2):190, 193-5. PubMed ID: 1111876 [TBL] [Abstract][Full Text] [Related]
44. [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3]. Giachino G; Giacchino F; Jeantet A; Del Piano A; Garetto A; Pellerey M; Piccoli G Minerva Med; 1985 Mar; 76(9-10):407-14. PubMed ID: 2984605 [No Abstract] [Full Text] [Related]
45. Serum phosphorus control in dialysis patients with aluminum hydroxide gel-containing cookies. Ogden DA; Hurley E; Witt E; Heitsman C; Cazee C Proc Clin Dial Transplant Forum; 1972; 2():166-70. PubMed ID: 4681306 [No Abstract] [Full Text] [Related]
46. Aluminum in chronic hemodialysis. Possible influence on osteomalacic bone disease. Quarello F; Giachino G; Bossi P; Gilli G; Corrao G; Scursatone E; Jeantet A; Bossi R; Coppo R; Piccoli G; Vercellone A Minerva Nefrol; 1980; 27(4):635-44. PubMed ID: 7254691 [No Abstract] [Full Text] [Related]
47. [Renal osteodystrophy and growth in children undergoing CAPD]. Ito T; Horiike S; Iitaka K Nihon Jinzo Gakkai Shi; 1991 Aug; 33(8):779-90. PubMed ID: 1770638 [TBL] [Abstract][Full Text] [Related]
48. [Changes of PTH, 1,25(OH)2D3 and biochemistry in renal osteodystrophy]. Jia JK; Lou DX; Zhu P Zhonghua Nei Ke Za Zhi; 1994 Jan; 33(1):33-6. PubMed ID: 8045186 [TBL] [Abstract][Full Text] [Related]
52. Bone disease in patients dialyzed with untreated water. Rashid A; Posen GA; Gray D; Jaworski ZF Med Instrum; 1974; 8(3):204-6. PubMed ID: 4838450 [No Abstract] [Full Text] [Related]
53. Serum aluminium in haemodialysis patients: relation to osteodystrophy, encephalopathy and aluminium hydroxide consumption. Heaf JG; Nielsen LP Miner Electrolyte Metab; 1984; 10(6):345-50. PubMed ID: 6503890 [TBL] [Abstract][Full Text] [Related]
54. Fluoride metabolism in uremia. Nielsen E; Solomon N; Goodwin NJ; Siddhivarn N; Galonsky R; Taves D; Friedman EA Trans Am Soc Artif Intern Organs; 1973; 19():450-5. PubMed ID: 4722761 [No Abstract] [Full Text] [Related]
55. 1,25-dihydroxycholecalciferol in patients with chronic renal failure. Henderson RG; Ledingham JG; Norman AW; Oliver DO; Preston C; Russell RG; Small DG; Smith R; Warner GT; Woods CG Proc Eur Dial Transplant Assoc; 1973; 10(0):202-9. PubMed ID: 4802654 [No Abstract] [Full Text] [Related]
56. [Potentials for the early diagnosis of renal osteodystrophy in patients with chronic kidney failure during treatment by systematic hemodialysis]. Shcherbakova EO; Fekson EG; Cherniakov VL; Shcherbakov VA Urol Nefrol (Mosk); 1985; (2):58-60. PubMed ID: 3992758 [No Abstract] [Full Text] [Related]
57. [Pathological analysis of renal osteodystrophy in 194 cases]. Yu YF Zhonghua Bing Li Xue Za Zhi; 1991 Dec; 20(4):280-3. PubMed ID: 1813163 [TBL] [Abstract][Full Text] [Related]